Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay.

Bosanquet, A G; Johnson, S A; Richards, S M

Bosanquet, A G; Johnson, S A; Richards, S M.

Affiliation

Bosanquet AG; Bath Cancer Research Unit, School of Postgraduate Medicine, University of Bath, Royal United Hospital, Bath. a.g.bosanquet@bath.ac.uk

Br J Haematol ; 106(1): 71-7, 1999 Jul.

Article in En | MEDLINE | ID: mdl-10444165

Subject(s)

Antineoplastic Agents/therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Vidarabine/analogs & derivatives; Aged; Cause of Death; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Survival Analysis; Survival Rate; Therapeutics; Vidarabine/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Vidarabine / Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Agents Type of study: Etiology_studies / Prognostic_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Haematol Year: 1999 Document type: Article Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links